Journals / Turkish Journal of Pediatrics / 2016 / Cilt: 58 - Sayı: 4

Is anti-Mullerian hormone an indicator of potential polycystic ovary syndrome in prepubertal girls with simple obesity?

Pages
406–412
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies, however, are needed due the limited number of subjects in this study and in the absence of adequate relevant data.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Korkmaz Ö, Gökşen D, Özen S, Darcan Ş.
📊
Key Findings & Data:Turk J Pediatr 2016; 58: 406-412.The aim of this anti-Mullerian hormone (AMH) levels in prepubertal obese girls are a predictive marker for polycystic ovary syndrome (PCOS) and to investigate the relationship between insulin resistance and AMH.
💡
Conclusion & Impact:Further studies, however, are needed due the limited number of subjects in this study and in the absence of adequate relevant data.
🔬Design:Modeling & Simulation
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Özet

Korkmaz Ö, Gökşen D, Özen S, Darcan Ş. Is anti-Mullerian hormone an indicator of potential polycystic ovary syndrome in prepubertal girls with simple obesity? Turk J Pediatr 2016; 58: 406-412.The aim of this anti-Mullerian hormone (AMH) levels in prepubertal obese girls are a predictive marker for polycystic ovary syndrome (PCOS) and to investigate the relationship between insulin resistance and AMH. Sixty girls with premature pubarche or obesity and 20 healthy controls between the ages of 6-9 were enrolled. Of the patients, 22 (36.7%) were in the obese group (Group 1), 28 (46.7%) in the early pubarche group (Group 2) and 10 (16.6%) in the early pubarche + obese group (Group 3). Comparison of the subjects' fasting insulin and homeostatic model assessment insulin resistance (HOMA-IR) demonstrated significantly higher values for group 1 compared to group 2 (p=0.001 and 0.001) and, likewise, significantly higher values for group 3 compared to group 2. There was no significant differences between all groups for AMH levels.AMH levels were not significantly different in the obese girls compared to the other groups. There was also no relationship between AMH and insulin resistance in any of the groups. Further studies, however, are needed due the limited number of subjects in this study and in the absence of adequate relevant data.

🔖

Cite This Article

KORKMAZ, Ö., GÖKŞEN, D., ÖZEN, S., DARCAN, Ş. (2016). Is anti-Mullerian hormone an indicator of potential polycystic ovary syndrome in prepubertal girls with simple obesity?. Turkish Journal of Pediatrics, Cilt: 58 - Sayı: 4, 406–412. https://ajindex.com/articles/412224

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Pellatt L, Rice S, Mason HD. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010; 139: 825-833
  2. Itman C, Mendis S, Barakat B, Loveland KL. All in the family: TGF-beta family action in testis development. Reproduction 2006; 132: 233-246
  3. Norman RJ, Wu R, Stankiewicz MT. Polycystic ovary syndrome. Med J Aust 2004; 180: 132-137
  4. Utriainen P, Jaaskelainen J, Voutilainen R. Serum antimullerian hormone concentrations in prepubertal girls with and without premature adrenarche: The influence of body mass index. Horm Res Paediatr 2010; 74: 207-211
  5. Crisosto N, Codner E, Maliqueo M, et al. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2739-2743
  6. Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum Mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005; 84: 938- 944
  7. La Marca A, Orvieto R, Giulini S, et al. Mullerianinhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004; 82: 970-972
  8. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol (Oxf) 2001; 55: 667-672
  9. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 162-168
  10. Greulich WW, Pyle Sl. Radiographic Atlas of Skeletal Devolepment of the Hand and Wrist. (2nd ed). Stanford: Stanford University Press, 1958: 125-228
  11. Tanner JM. Recording adolescent physical changes: Tanner system. Del Med J 1973; 45: 84-88
  12. Neyzi O, Binyıldız P, Alp H. Türk çocuklarında büyüme ve gelişme normları. I-tartı ve boy değerleri. İstanbul Tıp Fakültesi Mecmuası, 1978; 41 (Suppl.74): 1-22
  13. Kajaia N, Binder H, Dittrich R, et al. Low sex hormonebinding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 2007; 157: 499-507
  14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800
  15. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90: 3236-3242
  16. Eldar-